

15 March 2024

Company Announcements Office  
Australian Securities Exchange

## **Organisational Announcement: Chief Technology Officer**

Nanosonics (ASX: NAN), today announced that after more than 30 years in medical device development, seven of those with Nanosonics, its Chief Technology Officer, Dr Steven Farrugia will be retiring. Steve has chosen the timing of his retirement to coincide with the upcoming FDA regulatory submission of the Company's new CORIS technology, which signifies the achievement of the key technical milestones of the product.

Michael Kavanagh, CEO and Managing Director, said "Steve has played an integral role in the success of the Company. He enters retirement having established a highly competent and capable R&D department and leadership team to continue our commitment to innovation in infection prevention. In addition to the technical developments in our trophon franchise, Steve has also overseen the development of our new CORIS technology that will shortly be submitted for regulatory approval with the FDA. Together with the Board and all his colleagues I sincerely thank Steve for the significant contributions he has made to our growth and innovation and wish him all the best in his retirement".

Nanosonics has commenced the process to identify a successor for the CTO role. In the meantime, Steve will continue to consult with the Company for 12 months.

**Michael Kavanagh**  
**CEO / President**

This announcement has been authorised by the Board of Directors of Nanosonics.

**For more information, please contact:**

Michael Kavanagh, CEO / President on (02) 8063 1600.